PharmVar GeneFocus: CYP2D6-Reference-Cited by-同舟云学术

PharmVar GeneFocus: CYP2D6

Published:2019-12-09 Issue:1 Volume:107 Page:154-170
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Nofziger Charity¹^ORCID,Turner Amy J.²³^ORCID,Sangkuhl Katrin⁴,Whirl‐Carrillo Michelle⁴^ORCID,Agúndez José A.G.⁵⁶^ORCID,Black John L.⁷^ORCID,Dunnenberger Henry M.⁸^ORCID,Ruano Gualberto⁹,Kennedy Martin A.¹⁰^ORCID,Phillips Michael S.¹¹,Hachad Houda¹²^ORCID,Klein Teri E.⁴,Gaedigk Andrea¹³¹⁴^ORCID

Affiliation:

1. PharmGenetix GmbH Niederalm Austria

2. Section of Genomic Pediatrics Department of Pediatrics Children's Research Institute The Medical College of Wisconsin Milwaukee Wisconsin USA

3. RPRD Diagnostics LLC Wauwatosa Wisconsin USA

4. Department of Biomedical Data Science Stanford University Stanford California USA

5. University Institute of Molecular Pathology Biomarkers, UEx Cáceres Spain

6. ARADyAL Instituto de Salud Carlos III Madrid Spain

7. Division of Laboratory Genetics and Genomics Personalized Genomics Laboratory Mayo Clinic Laboratories Mayo Clinic Rochester Minnesota USA

8. Mark R. Neaman Center for Personalized Medicine NorthShore University HealthSystem Evanton Illinois USA

9. Institute of Living at Hartford Hospital Genomas Laboratory of Personalized Health Hartford Connecticut USA

10. Department of Pathology and Biomedical Science University Otago Christchurch New Zealand

11. Sequence Bioinformatics Inc St. John's Newfoundland Canada

12. Translational Software Bellevue Washington USA

13. Division of Clinical Pharmacology, Toxicology, & Therapeutic Innovation Children's Mercy Kansas City Kansas City Missouri USA

14. School of Medicine University of Missouri‐Kansas City Kansas City Missouri USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1643

Reference117 articles.

1. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

2. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

3. Clinical significance of the sparteine/debrisoquine oxidation polymorphism

4. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

5. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications;Frontiers in Pharmacology;2024-02-05

2. Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity;Human Genomics;2024-02-01

3. Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine;The Journal of Clinical Pharmacology;2024-01-04

4. Trends and implementation of preemptive pharmacogenomic testing;Comprehensive Precision Medicine;2024

5. Most patients with disorders of gut‐brain interaction receive pharmacotherapy with major or moderate drug‐gene interactions;Neurogastroenterology & Motility;2023-12-10